Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Infectious Disease

The Road to Recovery: Three Phases of Treatment

At a Glance

Treatment for cryptococcal meningitis usually has three phases: intensive initial therapy, a follow-up phase to suppress remaining fungus, and longer-term medicine to prevent relapse. The exact medicines and timing depend on HIV status, transplant history, immune status, and complications.

Treating cryptococcal meningitis is a marathon, not a sprint. Because this fungus is resilient, doctors use a three-phase strategy designed to first clear the infection, then mop up any remaining fungus, and finally prevent it from ever coming back [1][2].

The Three Phases of Treatment

Your treatment will follow these three distinct stages:

  1. Induction (Phase 1): The most intensive stage, managed in the hospital. The goal is to rapidly control the fungus in your spinal fluid and brain [1][3].
  2. Consolidation (Phase 2): A mid-term stage lasting about 8 weeks. Once the initial phase is complete, you switch to oral medication to ensure the infection is suppressed [4][5].
  3. Maintenance (Phase 3): A long-term stage lasting 6–12 months (or longer). You take a lower daily dose of oral medication to prevent the fungus from returning [4][2].

Choosing the Right Path: HIV-Associated Treatment

If you are an eligible adult living with HIV, the World Health Organization (WHO) updated its recommendations in 2022 based on new research (the AMBITION-cm trial) [1][6].

  • The AMBITION Regimen: A single high dose (10 mg/kg) of liposomal amphotericin B given through an IV on Day 1 [1][6].
  • The Follow-up: This is combined with 14 days of two other medications: flucytosine and high-dose fluconazole [6][1].
  • Why this change? This single-dose approach was found to be just as effective as daily IV treatments but with fewer side effects for this specific population [6][7]. It is not a universal option for every person with HIV, and your treating specialist will select the best regimen for you.

The Non-HIV and Transplant Path

It is vital to know that the “single-dose” regimen mentioned above was studied specifically for people with HIV, and your treating specialist will determine if it is appropriate for you. It is generally not recommended for patients who have had organ transplants, are otherwise immunocompromised, have severe neurological complications, or have C. gattii [8][9].

  • Longer Induction: These patients typically require a longer induction phase, often approximately 4 to 6 weeks of daily IV amphotericin B combined with flucytosine [2][10].
  • Careful Monitoring: For transplant recipients, your doctors must carefully balance these antifungals with your transplant medications, as they can interact [11][8].

Key Medications and Safety

  • Liposomal Amphotericin B: This is the preferred form of the “heavy hitter” antifungal. It is specially formulated to be less “toxic” to your kidneys than the older version (called deoxycholate) [12][11].
  • Flucytosine: This oral medication helps the amphotericin work better, but it must be taken exactly as prescribed (usually four times a day) to prevent the fungus from becoming resistant [6].
  • Fluconazole: This is the primary medication used in the consolidation and maintenance phases. While easier to take than IV drugs, you will likely be on it for a year or more to stay safe [4][2].

Timing Other Medications

If you are starting HIV treatment (ART) for the first time, your doctors will likely wait 4 to 6 weeks after starting your antifungal treatment before beginning ART [12][13]. Starting both at the same time can cause a dangerous inflammatory reaction called IRIS (Immune Reconstitution Inflammatory Syndrome), where your recovering immune system “overreacts” to the fungus [13][14].

Common questions in this guide

What are the three phases of cryptococcal meningitis treatment?
Induction is the intensive first phase, usually managed in the hospital to rapidly control the fungus in the brain and spinal fluid. Consolidation follows for about 8 weeks, and maintenance uses a lower oral dose for 6 to 12 months or longer to prevent the infection from returning.
Can every person with HIV receive the single-dose amphotericin regimen?
No. The single 10 mg/kg dose of liposomal amphotericin B followed by 14 days of flucytosine and high-dose fluconazole was studied for eligible adults with HIV. People with transplants, other immune suppression, severe neurologic complications, or C. gattii may need a different, longer regimen selected by a specialist.
How long does induction treatment for cryptococcal meningitis last?
The duration depends on HIV status, immune status, transplant history, the infecting species, and neurologic complications. Some eligible adults with HIV receive the single-dose regimen followed by 14 days of two oral medicines, while transplant recipients and other higher-risk patients often need about 4 to 6 weeks of daily IV amphotericin B with flucytosine.
Why is liposomal amphotericin B used, and what will doctors monitor?
Liposomal amphotericin B is preferred because its formulation is generally less harmful to the kidneys than the older deoxycholate form. Doctors may monitor kidney function and potassium closely while you receive it, especially during intensive treatment.
When can I start HIV treatment after cryptococcal meningitis treatment begins?
For people starting HIV treatment for the first time, clinicians often wait about 4 to 6 weeks after antifungal therapy begins before starting antiretroviral therapy. This delay can lower the risk of IRIS, a potentially dangerous inflammatory reaction as the immune system recovers.
How long will I need to take fluconazole?
Fluconazole is commonly used during the roughly 8-week consolidation phase and the longer maintenance phase. Maintenance often lasts 6 to 12 months or longer, and your specialist will determine the duration based on your immune status and response.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Cryptococcal meningitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I following the 'single-dose' or 'daily dose' induction protocol, and why is that the right choice for me?
  2. 2.Are we using the lipid-formulation (liposomal) of amphotericin B to help protect my kidneys?
  3. 3.How long do you expect my induction phase to last before I can switch to just taking pills?
  4. 4.When can I safely start (or restart) my HIV or transplant medications?
  5. 5.What are my latest potassium and kidney function levels, and are they being monitored daily?

References

References (14)
  1. 1

    Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?

    Milsap D, Okuno M, Kigozi E, et al.

    Microorganisms 2025; (13(4)) doi:10.3390/microorganisms13040847.

    PMID: 40284683
  2. 2

    Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients.

    Beardsley J, Sorrell TC, Chen SC

    Journal of fungi (Basel, Switzerland) 2019; (5(3)) doi:10.3390/jof5030071.

    PMID: 31382367
  3. 3

    Recent advances in managing HIV-associated cryptococcal meningitis.

    Boyer-Chammard T, Temfack E, Alanio A, et al.

    F1000Research 2019; (8()) doi:10.12688/f1000research.17673.1.

    PMID: 31275560
  4. 4

    Once-Weekly Liposomal Amphotericin B Use for Maintenance and Consolidation Phase Treatment of Cryptococcal Meningitis in Patients With AIDS.

    Belinschi V, Iheagwara C, Muhanna A

    Cureus 2024; (16(3)):e55824 doi:10.7759/cureus.55824.

    PMID: 38590504
  5. 5

    Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.

    Merry M, Boulware DR

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (62(12)):1564-8 doi:10.1093/cid/ciw151.

    PMID: 27009249
  6. 6

    Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.

    Jarvis JN, Lawrence DS, Meya DB, et al.

    The New England journal of medicine 2022; (386(12)):1109-1120 doi:10.1056/NEJMoa2111904.

    PMID: 35320642
  7. 7

    How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?

    Harrison TS, Lawrence DS, Mwandumba HC, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; (76(5)):944-949 doi:10.1093/cid/ciac792.

    PMID: 36166405
  8. 8

    Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies.

    Yoon H, Pirofski LA, Boulware DR

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (81(5)):917-922 doi:10.1093/cid/ciaf218.

    PMID: 40279203
  9. 9

    Infectious Diseases Physician Management of Cryptococcal Meningitis in North America-Is Single High-Dose Liposomal Amphotericin B Being Used?

    Bahr NC, Beekmann SE, Polgreen PM, et al.

    Open forum infectious diseases 2024; (11(6)):ofae120 doi:10.1093/ofid/ofae120.

    PMID: 38887490
  10. 10

    Treatment of cryptococcosis in non-HIV immunocompromised patients.

    Henao-Martínez AF, Chastain DB, Franco-Paredes C

    Current opinion in infectious diseases 2018; (31(4)):278-285 doi:10.1097/QCO.0000000000000458.

    PMID: 29738314
  11. 11

    Cryptococcosis in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Baddley JW, Forrest GN,

    Clinical transplantation 2019; (33(9)):e13543 doi:10.1111/ctr.13543.

    PMID: 30900315
  12. 12

    New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.

    Temfack E, Boyer-Chammard T, Lawrence D, et al.

    Current neurology and neuroscience reports 2019; (19(10)):81 doi:10.1007/s11910-019-0993-0.

    PMID: 31673881
  13. 13

    Integrated therapy for HIV and cryptococcosis.

    Srichatrapimuk S, Sungkanuparph S

    AIDS research and therapy 2016; (13(1)):42 doi:10.1186/s12981-016-0126-7.

    PMID: 27906037
  14. 14

    Corticosteroids for the management of severe intracranial hypertension in meningoencephalitis caused by Cryptococcus gattii: A case report and review.

    Maciel RA, Ferreira LS, Wirth F, et al.

    Journal de mycologie medicale 2017; (27(1)):109-112 doi:10.1016/j.mycmed.2016.09.003.

    PMID: 27818191

This page is for informational purposes only and does not constitute medical advice. Your infectious disease team must tailor antifungal medicines, monitoring, and HIV or transplant medication timing to your situation.